SCHEMBL3498936

SCHEMBL3498936

CCOC(=O)c1cc2ccc(-c3ccc(Cl)cc3)cc2[nH]1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.80
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 3/20 0.61
HPGD P15428 3/20 0.61
RAB9A P51151 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
NPC1 O15118 2/20 0.61
LMNA P02545 2/20 0.61
MEN1 O00255 1/20 0.61
GLA P06280 1/20 0.61
GAA P10253 1/20 0.61
MAPT P10636 1/20 0.61
KMT2A Q03164 1/20 0.61
ATM Q13315 1/20 0.61
MMP13 P45452 6/20 0.60
MMP2 P08253 4/20 0.60
MMP14 P50281 3/20 0.60
ALPL P05186 1/20 0.57
HSD17B10 Q99714 1/20 0.56
HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500194 0.90 MMP13 (0.75) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL7216497 0.89 ALOX15 (0.67) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL30190576 0.89 ALOX15 (1.00) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL615882 0.89 ALOX15 (1.00) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL30071378 0.87 ALOX15 (0.64) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL20494524 0.87 ALOX15 (0.64) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL20494474 0.85 ALOX15 (0.57) ALOX15MAPTPIP4K2A
SCHEMBL30071278 0.85 ALOX15 (0.57) ALOX15MAPTPIP4K2A
SCHEMBL5737506 0.85 ALOX15 (0.61) ALOX15KDM4EALDH1A1HPGDRAB9A
SCHEMBL31264281 0.81 ALOX15 (0.79) ALOX15KDM4EALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 ALOX15 3049/4885KDM4E 2059/4885ALDH1A1 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.